Reflections on Effect of Stand Up To Cancer

Editor’s note: You may have heard of the charitable program Stand Up to Cancer, which has raised hundreds of millions of dollars to support cancer research. This article discusses the effects of the program.

“The week before Stand Up To Cancer‘s (SU2C) fourth-biennial live 1-hour commercial-free prime time roadblock telecast on Sept. 5, Nobel Laureate Phillip A. Sharp, PhD, shared his views about the efficacy of this mass media approach to educating the public about cancer and cancer research.

“Sharp, Institute Professor at the Massachusetts Institute of Technology (MIT) and David H. Koch Institute for Integrative Cancer Research at MIT, has chaired Stand Up’s Scientific Advisory Committee (SAC) since it was founded in 2008, by the not-for-profit Entertainment Industry Foundation (EIF), the film and television industry’s 501(c)(3) philanthropic arm.

“With telecasts in September 2008, 2010, and 2012, the television specials have so far raised more than $261 million for innovative cancer research programs including 12 scientific ‘dream teams,’ two translational research teams, and 26 young scientists involved in ‘high-risk, potentially high-reward projects’ that might not have been funded through traditional funding mechanisms.”


Multidisciplinary Team Tackles Personalized Medicine for Melanoma Patients with Normal BRAF Gene


A group of melanoma researchers and clinicians have received funding to address an important question in melanoma treatment: are there molecular targets for melanomas that do not harbor a mutation in the BRAF gene? And can we identify drug candidates for these new molecular targets? The Stand Up to Cancer (SUC2) philanthropic program and the Melanoma Research Alliance are jointly funding the 3-year, eight-institution endeavor. Continue reading…


Collaborative Effort Aims to Find Strategies to Preempt Resistance to Prostate Cancer Therapies


The ‘Targeting Adaptive Pathways in Metastatic Treatment-Resistant Prostate Cancer’ 3-year project aims to understand how prostate tumors become resistant to two newer drugs for prostate cancer that target the androgen receptor pathway—enzalutamide and abiraterone acetate. Continue reading…


Prostate Cancer ‘Dream Teams’ Lay Out Project Plans to Target Treatment-Resistant Prostate Cancer and to Identify New Prostate Cancer Subgroups


Last week, cancer researchers gathered in Washington, D.C., to attend the American Association for Cancer Research (AACR) annual meeting. At the meeting, two large-scale projects to improve the treatment of prostate cancer and prolong patients’ survival were outlined in presentations by two prominent researchers and clinicians: Arul M. Chinnaiyan, MD, PhD, a professor of urology at the University of Michigan and director of the Michigan Center for Translational Pathology in Ann Arbor, Michigan, and Eric J. Small, MD, the deputy director of clinical sciences at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center. Continue reading…